Jci_page_head_homepage_01 Jci_page_head_homepage_02
Baskaran Govindarajan, James E. Sligh, Bethaney J. Vincent, Meiling Li, Jeffrey A. Canter, Brian J. Nickoloff, Richard J. Rodenburg, Jan A. Smeitink, Larry Oberley, Yuping Zhang, Joyce Slingerland, Rebecca S. Arnold, J. David Lambeth, Cynthia Cohen, Lu Hilenski, Kathy Griendling, Marta Martínez-Diez, José M. Cuezva, Jack L. Arbiser
Published in Volume 117, Issue 3
J Clin Invest. 2007; 117(3):719–729 doi:10.1172/JCI30102
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 4
Akt inhibition downregulates VEGF, rictor, and Sirt1.

(A) Triplicate analysis of pooled WM35 cells transfected with Akt demonstrated activation (phosphorylation) of JunD in melanoma tumors. Lane 1, WM35 cells; lane 2, WM35 PKBDD cells (which have numerous mitochondrial mutations); lane 3, pooled WM35 cells freshly transfected with active PKB prior to tumor implantation; lanes 4–6, protein from individual tumors derived after injection of pooled WM35 PKB cells into mice. (BD) Akt inhibition in A375 melanoma cells resulted in downregulation of VEGF (B), rictor (C), and Sirt1 (D) RNA. A375 cells were treated with Akt inhibitor and harvested at 2 and 24 hours. RNA levels are corrected for 18S RNA, and experiments were performed in triplicate. *P < 0.05 versus vehicle.